MYSM1 as a histone H2A deubiquitinase has been reported to activate the transcription of its downstream genes, including CDH1, c-MET, or genes encoding ribosomal proteins via histone H2A deubiquitination in colorectal cancer, melanoma, and B cell lymphoma (Chen et al, 2021; Lin et al, 2021; Wilms et al, 2017). This evidence concerns the gene CDH1 and B-cell non-Hodgkin lymphoma.